Pipeline

16 Pipelines Reached PCC in Six Months40+ More Advancing

16 pipelines progress overview

Automated Wet-Lab PlatformHigh-Throughput Protein Production and Profiling

2,000 proteins per run | 8-day end-to-end workflow From gene synthesis to full property readout

Gene Synthesis

1 DayGene synthesis at scale

Expression & Purification

5 DaysExpression and purification

Property Profiling

2 DaysMulti-parameter characterization
Properties profiledBLI affinity • specificity • expressibility • stability • humanization level • purity • immunogenicity

Affinity Screening,Blocking and Functional Activity Testing

anti-IL23: BLI affinity (KD) across three design-test rounds
BLI affinity KD results across three design-test rounds

Y axis is log KD; higher = stronger. The ★ and dotted line of the same colour are the same number (wt measured value / that value extended as a reference), so the line passes through the star. Open circle + arrow = kdis at the BLI limit (<1e-7); that KD is an upper bound only.

Key numbers per round
Key affinity numbers per design round
Three Rounds of Iteration Improved Affinity by 10-1,000x
Bar chart showing affinity improvement across three rounds
Humanized antibodies blocking CD27 binding to cells
Strong Blocking and Functional Activity
Blocking activity test results for selected antibodies
Dose response curve in ADCC bioassay

Three Humanized Antibodies Delivered IC50 Values Slightly Better than the Benchmark. These Four Antibodies Were Selected for Mid-Scale Expression and Preliminary Developability Assessment.

Case A: Humanized Antibody Purity Testing (SEC)

High Purity and Low Aggregation

MJ00A hz006 2H9 SEC result
MJ00A_hz006_2H9 SEC Result
MJ00A 2H9-Hz1 SEC result
MJ00A_2H9-Hz1 SEC Result
MJ00A 2G1-Hz5 SEC result
MJ00A_2G1-Hz5 SEC Result

Initial In Vivo Efficacy and Safety Assessment

Initial in vivo efficacy assessment imaging results

In Vivo Results Show That the Candidate Molecules Delivered Good Efficacy and Were Close to the Benchmark. At the Same Time, No Obvious Toxic Side Effects Such as Weight Loss or Hair Loss Were Observed.

Initial in vivo safety assessment table